- Title: Subtitle
- WCN25-2041 EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH C3 GLOMERULOPATHY: 12-MONTH RESULTS FROM THE PHASE 3 APPEAR-C3G STUDY
- Creators
- Carla Nester - University of IowaRichard Smith - University of IowaDavid Kavanagh - Newcastle UniversityMarina Vivarelli - Bambino Gesù Children's HospitalGiuseppe Remuzzi - Nephrology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, ItalyMing-Hui Zhao - Peking University First HospitalEdwin Wong - Newcastle UniversityYaqin Wang - Novartis (China)Angelo Trapani - Novartis (United States)Induja Krishnan - Nephrology, Novartis Pharmaceuticals Corporation, East Hanover, United StatesNicholas Webb - Novartis (Netherlands)Matthias Meier - Novartis (Netherlands)Andrew Bomback - Columbia University
- Resource Type
- Abstract
- Publication Details
- Kidney international reports, Vol.10(2 Supplement), pp.S136-S137
- DOI
- 10.1016/j.ekir.2024.11.300
- ISSN
- 2468-0249
- eISSN
- 2468-0249
- Publisher
- Elsevier Inc
- Language
- English
- Date published
- 02/2025
- Academic Unit
- Roy J. Carver Department of Biomedical Engineering; Molecular Physiology and Biophysics; Anatomy and Cell Biology; Nephrology, Dialysis and Transplantation; Stead Family Department of Pediatrics; Iowa Neuroscience Institute; Otolaryngology; Internal Medicine
- Record Identifier
- 9984775017802771
Abstract
WCN25-2041 EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH C3 GLOMERULOPATHY: 12-MONTH RESULTS FROM THE PHASE 3 APPEAR-C3G STUDY
Kidney international reports, Vol.10(2 Supplement), pp.S136-S137
02/2025
DOI: 10.1016/j.ekir.2024.11.300
Details
Metrics
24 Record Views